Vyome Holdings — Second Quarter 2026 Earnings Summary

Financial Performance

• Cash and cash equivalents increased to approximately $7.9 million as of June 30, 2026, from approximately $5.0 million as of December 31, 2025.
• Total current assets were approximately $8.2 million as of June 30, 2026.
• Total stockholders' equity was approximately $7.3 million as of June 30, 2026, compared to approximately $3.8 million as of December 31, 2025.
• Total operating expenses for the quarter ended June 30, 2026, were approximately $874,000, comprising $507,000 in research and development expenses and $365,000 in selling, general, and administrative expenses.
• Net loss attributable to common shareholders for the quarter ended June 30, 2026, was approximately $720,000, or $0.10 per basic and diluted share.
• For the six months ended June 30, 2026, revenues were $58,546 compared to $248,535 for the same period in 2025.
• Gross profit for the six months ended June 30, 2026, was $28,303, down from $178,654 in the same period of 2025.
• Operating expenses for the six months ended June 30, 2026, were $2,020,809, compared to $701,839 in the same period of 2025.
• Net loss for the six months ended June 30, 2026, was $1,705,204, compared to $602,732 in the same period of 2025.
• The company maintains a clean capital structure with no debt, no preferred stock, and no toxic financing instruments.

Guidance and Future Outlook

• The company plans to incorporate FDA feedback on the proposed clinical development program and intends to continue engagement with the FDA through a Type C meeting.
• Vyome intends to advance new JAK inhibitor assets in a disciplined manner using non-dilutive methods while keeping VT-1953 as the primary development focus.
• Management believes the company is well-positioned to pursue development priorities and create long-term shareholder value given its strong balance sheet and disciplined capital structure.

Business Segments and Product Lines

• VT-1953 Program: Phase 2 data presented at the AACR demonstrated statistically significant improvements in malodor (primary endpoint), patient-reported impact of malodor on daily life, and lesion pain, with no treatment-emergent adverse events reported.
• Regulatory Status: In March 2026, a pre-IND briefing package was submitted to the FDA including the proposed pivotal clinical study strategy for malignant fungating wounds; the FDA's written response was received during the second quarter of 2026.
• Pipeline Expansion: An agreement was signed with Impetis Biosciences Limited to in-license two selective JAK inhibitor assets designed for higher selectivity to potentially treat autoimmune and inflammatory conditions.
• Intellectual Property: Received a granted Chinese patent covering formulation and therapeutic use claims related to the VB-1953 topical gel program for treating inflammatory acne.

Market and Competitive Landscape

• The company focuses on immuno-inflammatory and rare disease conditions, specifically targeting malignant fungating wounds and inflammatory acne.
• Vyome positions itself as building a premier platform spanning the US-India innovation corridor.

Risks and Challenges

• Risks include the ability to raise capital to fund continuing operations.
• Uncertainties surround the timing and outcome of interactions with the FDA.
• Challenges include the ability to successfully design, initiate, enroll, and complete clinical trials.
• Risks exist regarding the ability to protect intellectual property rights and the impact of infringement actions or litigation.
• Competition from other providers and products is a noted factor.
• Changes in government regulation could impact operations.

Management Commentary and Tone

• Krishna Gupta, Chairman, stated the company continues to execute with focus and discipline, maintaining a methodical and conservative approach to capital allocation while advancing the lead program and strengthening the IP portfolio.
• Venkat Nelabhotla, President and CEO, emphasized VT-1953 as the lead priority, citing the safety profile and statistical significance of Phase 2 data.
• Management expressed confidence in the combination of focused clinical execution, pipeline optionality, and financial discipline as a strong foundation for long-term shareholder value.

Other Key Points

• The press release includes a forward-looking statement disclaimer regarding the Private Securities Litigation Reform Act of 1995.
• Complete financial results are available in the Company's Quarterly Report on Form 10-Q filed with the SEC.
• The company is building a platform leveraging its clinical-stage assets to transform patient lives in immuno-inflammatory conditions.